Biodegradable Polymer

Biodegradable Polymer refers to a macromolecular material capable of breaking down into simpler compounds through enzymatic, hydrolytic, or microbial action under physiological or environmental conditions, ultimately assimilating into biological systems without accumulating as persistent waste. These materials degrade into non toxic byproducts including water, carbon dioxide, and biomass, offering sustainable alternatives to conventional polymers in pharmaceutical applications. Common biodegradable polymers include polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), and naturally derived materials like chitosan and hyaluronic acid.

The pharmaceutical industry extensively employs biodegradable polymers in controlled release formulations, implantable drug delivery systems, tissue engineering scaffolds, and surgical materials that eliminate need for removal procedures. These materials enable sustained therapeutic delivery over weeks to months as polymer degradation gradually releases incorporated drugs, improving patient compliance and therapeutic outcomes. Formulation scientists carefully select polymers based on degradation kinetics, mechanical properties, biocompatibility, and manufacturing compatibility to match specific application requirements. Regulatory pathways for biodegradable polymer devices and drug products are well established, with extensive safety data supporting their use. Manufacturing processes including extrusion, injection moulding, electrospinning, and spray drying transform polymers into diverse product formats. The industry advances next generation biodegradable polymers with improved properties, exploring stimuli responsive systems that degrade in response to specific biological triggers, composite materials combining multiple polymers for tailored performance, and surface modified variants with enhanced biocompatibility. As long acting injectable formulations and implantable devices gain market share, biodegradable polymer technology remains central to developing patient friendly delivery platforms that improve therapeutic efficacy while minimising environmental impact.